Skip to main content
. 2024 Mar 11;41(5):1860–1884. doi: 10.1007/s12325-024-02817-w

Table 1.

Demographic and health characteristics in participants with MDD versus without MDD

Characteristic With MDD (n = 10,710) Without MDD* (n = 52,687)
Age, mean (SD), years 44.4 (16.3)a 49.4 (17.3)b
Female, n (%) 7558 (70.6)a 27,957 (53.1)b
Race and ethnicity, n (%)
 African American 943 (8.8)a 5922 (11.2)b
 American Indian 90 (0.8)a 255 (0.5)b
 Asian 366 (3.4)a 4384 (8.3)b
 Hispanic 1206 (11.3)a 5579 (10.6)b
 Multiracial 414 (3.9)a 929 (1.8)b
 White 7573 (70.7)a 34,923 (66.3)b
 Other 118 (1.1)a 695 (1.3)a
Marital status: single/not living with partner, n (%) 5706 (53.3)a 20,994 (39.9)b
Less than university education, n (%) 4875 (45.5)a 18,205 (34.6)b
Annual household income, n (%)
 < $25,000 2497 (23.3)a 6243 (11.9)b
 $25,000 to < $50,000 2961 (27.7)a 10,168 (19.3)b
 $50,000 to < $75,000 1949 (18.2)a 9570 (18.2)a
 > $75,000 2928 (27.3)a 23,930 (45.4)b
 Declined to answer 375 (3.5)a 2776 (5.3)b
Unemployed,± n (%) 4889 (45.7)a 20,597 (39.1)b
Long- or short-term disability, n (%) 944 (8.8)a 887 (1.7)b
Health insurance type, n (%)
 Coverage through employer§ 4595 (42.9) 24,657 (46.8)
 Medicare 2194 (20.5)a 12,217 (23.2)b
 Medicaid/MediCal 1367 (12.8)a 2636 (5.0)b
 Other insurance coverage# 1354 (12.6) 6252 (11.9)
 No insurance 1016 (9.5)a 5781 (11.0)b
 Unsure 184 (1.7)a 1144 (2.2)b
Number of comorbid mental health diagnoses, mean (SD) 1.6 (1.5)a 0.1 (0.5)b
Other mental health disorders, n (%)
 Anxiety 6628 (61.9)a 2636 (5.0)b
 GAD 3574 (33.4)a 1181 (2.2)b
 Social anxiety disorder 1761 (16.4)a 347 (0.7)b
 PTSD 1269 (11.9)a 256 (0.5)b
 Panic disorder 1145 (10.7)a 273 (0.5)b
 OCD 823 (7.7)a 283 (0.5)b
 ADD 724 (6.8)a 485 (0.9)b
 ADHD 454 (4.2)a 356 (0.7)b
 Phobias 216 (2.0)a 69 (0.1)b
 Dementia 28 (0.3)a 50 (0.1)b
Do not exercise, n (%) 4298 (40.1)a 14,200 (27.0)b
Current smoker, n (%) 2056 (19.2)a 6425 (12.2)b
BMI, mean (SD), kg/m2 30.0 (8.3)a 27.2 (6.5)b
CCI, mean (SD) 0.67 (1.3)a 0.34 (0.9)b
PHQ-9 score (0–27), mean (SD) 9.8 (6.7)a 3.5 (5.7)b
GAD-7 score (0–21), mean (SD) 7.5 (5.6)a 2.6 (4.4)b
Time since diagnosis, mean (SD), years 13.8 (10.9)
Total number of depressive symptoms,|| mean (SD) 2.5 (0.9)
 Depressed mood and other emotional problems, n (%) 9225 (89.0)
 Mental changes, n (%) 5010 (48.3)
 Sleep pattern changes, n (%) 4700 (45.3)
Currently using prescribed medication for MDD, n (%) 6516 (60.8)
Medications currently being used, n (%)
 SSRI/SNRIs 5254 (80.6)
 Bupropion 1359 (20.9)
 Atypical antipsychotics/antipsychotic combination pills** 490 (7.5)
 TCA/TeCAs 215 (3.3)
 Other antidepressants†† 117 (1.8)
 Mood stabilizers 109 (1.7)
 MAOIs 6 (0.1)
Not currently using medication for depression, n (%) 4194 (39.2)
Previously used prescribed medication for MDD (if not on currently), n (%)‡‡ 2653 (63.3)
Medication adherence (0–100 VAS scale), mean (SD) 87.3 (22.9)

Superscripts in the same row represent pairwise comparisons between cohorts. Values with different superscripts are significantly different at P < 0.05; values without superscripts were not included in the test. In addition to pairwise comparison, one-way ANOVA was used to compare across groups for the following variables: age, CCI, BMI, number of comorbid mental health conditions, PHQ-9 scores, GAD-7 scores, time since diagnosis, total number of depressive symptoms, and medication adherence (all P < 0.001); all other variables (e.g., sex, race and ethnicity) were first compared across all groups using chi-square (all P < 0.001 except for sleep pattern changes, MAOIs [P < 0.01], current prescription medication use status, bupropion [P < 0.05] depressed mood and other emotional problems, SSRI/SNRIs, TCA/TeCAs, other antidepressants, mood stabilizers, and previously used a prescribed medication for MDD [P > 0.05])

ADD attention deficit disorder, ADHD attention deficit hyperactivity disorder, BMI body mass index, BP-I bipolar I disorder, CCI Charlson Comorbidity Index, GAD-7 Generalized Anxiety Disorder Assessment-7, GAD Generalized Anxiety Disorder, MAOI monoamine oxidase inhibitor, MDD major depressive disorder, MDQ Mood Disorder Questionnaire, OCD obsessive compulsive disorder, PHQ-9 Patient Health Questionnaire-9, PTSD post-traumatic stress disorder, SD standard deviation, SNRI serotonin and norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TCA tricyclic antidepressants, TeCA tetracyclic antidepressants, VAS visual analogue scale

*Participants without MDD also screened negative for BP-I on the MDQ

Sex was self-reported by participants as male or female

Other referred to participants who reported their race as “some other race or origin”

±Participants who reported their employment status as one of the following were considered unemployed: homemaker, retired, student, long-term disability, or short-term disability, not employed but looking for work, and not employed and not looking for work

§Refers to insurance coverage from the employer of the participant, their spouse/partner, or their parent/legal guardian; each category was significant at P < 0.05 in pairwise comparisons

Reflects the sum of participants with insurance coverage from their employer, their spouse/partner, or their parent/legal guardian; each category was significant at P < 0.05 in pairwise comparisons

#Other insurance coverage includes individual/family insurance plan through a State Health Exchange or purchased by the individual, or Veterans Administration of CHAMPUS/TRICARE

Reflects the sum of participants with individual/family insurance through a State Health Exchange or purchased by the individual, or insurance through Veterans Administration/CHAMPUS or TRICARE; in pairwise comparison, individual/family insurance through a State Health Exchange or purchased by the individual and insurance through Veterans Administration/CHAMPUS was significant at P < 0.05

||Of those currently experiencing symptoms, including depressed mood and other emotional problems, eating, sleep, or mental changes, social problems, and physical problems

**Includes the combination pills amitriptyline/perphenazine and fluoxetine/olanzapine

††Other antidepressants included mirtazapine and nefazodone

‡‡Percentage calculated from participants currently not on prescribed medication